{"grounding": "The blood-brain barrier is critically important for the treatment of both primary and metastatic cancers of the central nervous system (CNS). Clinical outcomes for patients with primary CNS tumors are poor and have not significantly improved in decades. As treatments for patients with extracranial solid tumors improve, the incidence of CNS metastases is on the rise due to suboptimal CNS exposure of otherwise systemically active agents. Despite state-of-the art surgical care and increasingly precise radiation therapy, clinical progress is limited by the ability to deliver an effective dose of a therapeutic agent to all cancerous cells. Given the tremendous heterogeneity of CNS cancers, both across cancer subtypes andwithin a single tumor, and the range of diverse therapies under investigation, a nuanced examination of CNS drug exposure is needed. With a shared goal, common vocabulary, and interdisciplinary collaboration, the field is poised for renewed progress in the treatment of CNS cancers.", "generated_text": "The blood-brain barrier (BBB) presents a significant challenge in the development of effective treatments for central nervous system (CNS) tumors. This review explores the implications of the BBB for experimental cancer therapeutics, focusing on its impact on drug delivery, pharmacokinetics, and pharmacodynamics. We examine recent advances in strategies to overcome the BBB, including novel drug formulations, targeted delivery systems, and methods to temporarily disrupt the barrier. The review also discusses the importance of considering BBB permeability in the early stages of therapeutic development for CNS tumors. Furthermore, we highlight the potential of emerging technologies, such as nanoparticle-based therapies and gene editing approaches, in addressing the BBB challenge. Understanding and addressing the BBB's role in drug efficacy is crucial for improving outcomes in patients with CNS tumors and advancing the field of neuro-oncology.", "label": 1}